Literature DB >> 2933747

Milrinone and thyroid hormone stimulate myocardial membrane Ca2+-ATPase activity and share structural homologies.

K M Mylotte, V Cody, P J Davis, F B Davis, S D Blas, M Schoenl.   

Abstract

We have recently shown that thyroid hormone in physiological concentrations stimulates sarcolemma-enriched rabbit-myocardial-membrane Ca2+-ATPase in vitro. In this study, milrinone [2-methyl-5-cyano-(3,4'-bipyridin)-6(1H)-one], a cardiac inotropic agent, was thyromimetic in the same system. At clinically achievable concentrations (50-500 nM), milrinone significantly stimulated membrane Ca2+-ATPase in vitro. This action was antagonized by W-7 [N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide], an agent that also blocks thyroid hormone action on the Ca2+-ATPase, at concentrations as low as 5 microM. Progressive additions of milrinone to membranes incubated with a fixed concentration of thyroxine (0.10 nM) or triiodothyronine resulted in a progressive obliteration of the thyroid hormone effect on Ca2+-ATPase. Amrinone [5-amino-(3,4'-bipyridin)-6(1H)-one], the parent bipyridine of milrinone, had no effect on myocardial Ca2+-ATPase activity. X-ray crystallographic analysis of milrinone and amrinone revealed structural homologies between the phenolic ring of thyroxine and the substituted ring of milrinone, whereas amrinone did not share these homologies. The mechanism(s) of the inotropic actions of thyroxine and of milrinone is not clearly understood, but these observations implicate Ca2+-ATPase, a calcium pump-associated enzyme, as one mediator of the effects on the heart of these two compounds.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2933747      PMCID: PMC391424          DOI: 10.1073/pnas.82.23.7974

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Separation of vesicles of cardiac sarcolemma from vesicles of cardiac sarcoplasmic reticulum. Comparative biochemical analysis of component activities.

Authors:  L R Jones; H R Besch; J W Fleming; M M McConnaughey; A M Watanabe
Journal:  J Biol Chem       Date:  1979-01-25       Impact factor: 5.157

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Cardiotonic activity of amrinone--Win 40680 [5-amino-3,4'-bipyridine-6(1H)-one].

Authors:  A A Alousi; A E Farah; G Y Lesher; C J Opalka
Journal:  Circ Res       Date:  1979-11       Impact factor: 17.367

4.  Involvement of cyclic AMP in the direct inotropic action of amrinone. Biochemical and functional evidence.

Authors:  P Honerjäger; M Schäfer-Korting; M Reiter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-12       Impact factor: 3.000

5.  In vitro stimulation of human red blood cell Ca2+-ATPase by thyroid hormone.

Authors:  P J Davis; S D Blas
Journal:  Biochem Biophys Res Commun       Date:  1981-04-30       Impact factor: 3.575

6.  Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.

Authors:  M Endoh; S Yamashita; N Taira
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

7.  Thyroid hormone binding by human serum prealbumin (TBPA). Electrophoretic studies of triiodothyronine-TBPA interaction.

Authors:  P J Davis; B S Handwerger; R I Gregerman
Journal:  J Clin Invest       Date:  1972-03       Impact factor: 14.808

8.  N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation.

Authors:  H Hidaka; Y Sasaki; T Tanaka; T Endo; S Ohno; Y Fujii; T Nagata
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

9.  Thyroid hormone stimulation in vitro of red blood cell Ca2+-ATPase activity: interspecies variation.

Authors:  F B Davis; J H Kite; P J Davis; S D Blas
Journal:  Endocrinology       Date:  1982-01       Impact factor: 4.736

10.  The Ca2+-pumping ATPase of heart sarcolemma. Characterization, calmodulin dependence, and partial purification.

Authors:  P Caroni; E Carafoli
Journal:  J Biol Chem       Date:  1981-04-10       Impact factor: 5.157

View more
  15 in total

Review 1.  Nongenomic actions of thyroid hormone.

Authors:  Paul J Davis; Fernando Goglia; Jack L Leonard
Journal:  Nat Rev Endocrinol       Date:  2015-12-15       Impact factor: 43.330

Review 2.  Comparison of the mechanisms of nongenomic actions of thyroid hormone and steroid hormones.

Authors:  P J Davis; H C Tillmann; F B Davis; M Wehling
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

3.  Cardiotonic agent milrinone stimulates resorption in rodent bone organ culture.

Authors:  N S Krieger; T S Stappenbeck; P H Stern
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

Review 4.  Milrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  R A Young; A Ward
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

5.  Milrinone attenuates thromboxane receptor-mediated hyperresponsiveness in hypoxic pulmonary arterial myocytes.

Authors:  K T Santhosh; O Elkhateeb; N Nolette; O Outbih; A J Halayko; S Dakshinamurti
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 6.  Studies on the mechanism of action of the bipyridine milrinone on the heart.

Authors:  A E Farah; C J Frangakis
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 7.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

8.  Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.

Authors:  E J Kelso; B J McDermott; B Silke
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

9.  Regulation of cardiac sarcolemmal Ca2+ channels and Ca2+ transporters by thyroid hormone.

Authors:  E K Seppet; F Kolar; I M Dixon; T Hata; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1993-12-22       Impact factor: 3.396

Review 10.  Phosphodiesterase III inhibitors: long-term risks and short-term benefits.

Authors:  J M Cruickshank
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.